Pharmacological targeting of TREM2 to suppress the inflammatory response and modifying ApoE ɛ4 isoform via CRISPA/cas9 may provide a new approach for developing therapeutic strategies in the treatment of neuroinflammation and other neurodegenerative diseases. The gene discussed is TREM2; the disease is neurodegenerative disease.